Avoiding radiation damage to salivary glands with Ac-225-PSMA-617 therapy

Posted on February 1, 2021 by Sitemaster

As we await the results of the VISION trial of Lu-177-PSMA-617, research continues into improving radiopharmaceuticals. … READ MORE …

Filed under: Drugs in development | Tagged: , , , , , , , | 3 Comments »

Ac-225-PSMA-617 in mCRPC: an update

Posted on January 14, 2018 by Sitemaster

We now have some details from clinical trials of the radiopharmaceutical actinium-225-PSMA-617 (Ac-225-PSMA-617) in very advanced prostate cancer patients. … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , | 9 Comments »

Ac-225-PSMA-617 apparently extends survival of very late-stage patients: an update

Posted on December 23, 2016 by Sitemaster

The nuclear medicine group at the University of Heidelberg in Germany recently reported a complete response in two patients treated with Ac-225-PSMA-617 (see this link). … READ MORE …

Filed under: Drugs in development, Management, Treatment | Tagged: , , , | 6 Comments »

A first-in-human trial of actinium-225-PSMA-617

Posted on July 15, 2016 by Sitemaster

Among the more interesting developments in radiation oncology/nuclear medicine in recent years are novel therapies created by attaching radioactive isotopes to molecules (called ligands) that attach to the prostate-specific membrane antigen (PSMA). … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , | 7 Comments »

  • Donate

  • Disclaimer

    News and information provided on this site should not be used for diagnosing or treating any health problem or disease.

    The “New” Prostate Cancer InfoLink is intended for informational purposes only. It is not engaged in rendering medical advice or professional services and is not a substitute for professional care. If you have or suspect you may have a health problem, please consult your healthcare provider.

  • Hot Posts …

  • … and Archives